Two of the nation’s top pharmaceutical lobbying groups have filed a lawsuit against Nevada’s insulin transparency law.
The suit claims that implementing the law would violate patient rights and nullify trade secret protections. The Nevada Independent reportsPharmaceutical Research and Manufacturers of America, and the Biotechnology Innovation Organization are asking the U.S. District Court to declare that provisions of the Nevada law are unconstitutional.
Democratic State Senator Yvanna Cancela sponsored the bill this past legislative session, marking the first of its kind in the nation that requires diabetes drug manufacturers to report costs and profits associated with production.